After an interesting year filled with milestones like welcoming our millionth user to FibriCheck, achieving reimbursement from healthcare insurers and working on exciting new collaborations, we’re delighted to share our biggest achievements with you.
Our strongest growth to date
We are proud to see that 2022 has been a year of tremendous growth, as we welcomed over 250.000 new users to our platform and received more than 3 million heart rhythm measurements, which brought our total amount of measurements to the milestone of 10 million. We were able to identify over 10.000 new cases of atrial fibrillation, while also bringing peace of mind to more than 100.000 users that experienced symptoms of AF, but had measurements that didn’t indicate a heart rhythm disorder. With all this new data, we were able to generate new insights which allowed us to learn and to keep innovating.
Better accessibility through collaboration with healthcare insurers
Making FibriCheck accessible to the wide public by getting reimbursed by healthcare insurers was one of our biggest goals in 2022. After all, monitoring your heart health should be affordable for everyone. Working towards reimbursement had been an ongoing effort that got rewarded in 2022.
In the beginning of the year, several Belgian healthcare insurers started offering a reimbursement of €20 per calendar year for digital healthcare apps that complied with the requirements of the mHealth Pyramid. To comply, an app must be in line with the European privacy legislation, and must be CE-approved as well as accepted by the Federal Agency for Medicines and Health Products. As FibriCheck already lived up to these standards since 2017, we were proud to see that our users could make use of this reimbursement.
At the end of 2022, our partnership with Helan made it possible for Helan’s clients to use FibriCheck for free for a year. This is a tremendous step in the right direction towards a healthcare system that focuses on disease prevention.
FibriCheck’s contributions to scientific progress through numerous publications and clinical trials
With more than 10 scientific publications and our active part in over 30 clinical trials, we were happy to contribute to scientific progress in the field of atrial fibrillation. Additionally, we prepared for the launch of our FibriCheck Academy, which is meant to share our expert knowledge on atrial fibrillation and PPG-technology. Apart from that, we also want to use the Academy to open up discussions and to share insights on the latest developments within the field of heart health.
The impact of our latest product upgrades
In 2022, our company made significant strides in enhancing our mobile application. We can now offer tailored education experiences to our users and meet the evolving needs of our target audience. Additionally, we upgraded our patient management features in the dashboard and introduced a symptom tracking solution, thus improving overall usability.
Further expansion to MENA and Asia-Pacific
The year 2022 marked several important new partnerships, such as the collaboration with Pfizer and AlTibbi, which allowed us to roll out the first of its kind awareness campaign to detect AF in the UEA. Together, we successfully integrated FibriCheck’s detection and monitoring capabilities into AlTibbi’s region-wide platform to support a large-scale detection campaign for atrial fibrillation. On top of that, patients were also provided with the appropriate medical content and telehealth services they needed. This integration showcases the potential of FibriCheck in creating a more efficient diagnostic pathway and directing patients faster towards the care that they need.
In Hong Kong, we launched another successful detection campaign together with Roche Diagnostics and DrGo. Through the integration of FibriCheck into Hong Kong’s leading digital health platform DrGo, Hongkongers are now able to measure their heart rhythm at any time. The Hong Kong Society for Rehabilitation also followed up on those who had results that showed a possibility of atrial fibrillation, thereby improving the efficiency of the users’ overall health management.
Leading the path of quality and compliance
We were acknowledged for our quality in various ways over the past year. We were amongst the first to pass ORCHA’s (Organisation for the Review of Care and Health Apps) rigorous assessment process, and we received a perfect rating for our health standards compliance from the leading global digital assessment agency.
Enhancing heart health monitoring with FibriCheck-as-a-Service
In 2022 we’ve also worked towards making FibriCheck more accessible by offering FibriCheck-as-a-Service, where our regulatory compliant SDK can be integrated into third party solutions. Our technology can also be integrated into medical records so that clinical workflows can be streamlined. You can find more info about our integration options on our website.
We are looking forward to 2023!
In 2023, we are determined to stay on our growth trajectory and to keep collaborating with innovative partners to change the future of heart health together. Adhering to quality standards will also remain of the highest importance to us, as we want to set the bar for quality within the digital heartcare space. We’re excited to share our journey with you, so keep an eye on our website and our socials!
Created on February 13th, 2023 at 10:35 am
Last updated on August 3rd, 2023 at 03:38 pm